Peptide Research Database

Access 7,487 peer-reviewed studies, clinical trials, and research papers on peptides. Filter by key research, study type, compound, and category. Direct links to full PubMed entries for comprehensive, evidence-based exploration.

Animal Study
Notable
PMID: 43000092
2026 Nov 09

FSTL1high hepatic stellate cells secrete CCL3 to activate the PI3K/AKT/mTOR pathway, initiating anoikis resistance and promoting hepatocellular carcinoma progression.

In a mouse study, in summary, HSCs with high FSTL1 expression inhibit anoikis in HCC cells through the CCL3-CCR5-PI3K/AKT/mTOR axis, thereby promoting tumor progression. Follistatin-like protein 1 (FSTL1) is a secreted protein of interest in this study, which examines its impact on liver cancer cells and further elucidates its role in HCC by activating the PI3K/AKT/mTOR pathway to induce anoikis resistance.

Wang Y, Wang H, Nie Y, Xue H, Zhou Y, Li C, Zhang C, Gu C

Hepatocellular carcinoma (HCC) ranks among the most prevalent malignant tumors globally. Approximately 90% of HCC cases arise in the context of liver fibrosis, with hepatic stellate cells (HSCs) playing a pivotal role in the fibrogenic process. Follistatin-like protein 1 (FSTL1) is a secreted protein of interest in this study, which examines its impact on liver cancer cells and further elucidates its role in HCC by activating the PI3K/AKT/mTOR pathway to induce anoikis resistance. The findings indicate that FSTL1 is predominantly localized in HSCs within HCC tissues and exhibits upregulated expression compared to cirrhotic tissues. Experimental manipulation of FSTL1 expression, through stable overexpression or knockdown, correspondingly enhanced or inhibited the proliferation and migration capabilities of HSCs in vitro. Furthermore, HSCs with high FSTL1 expression were observed to facilitate the migration, invasion, in vivo growth, and epithelial-mesenchymal transition (EMT) of HCC cells. In particular, HSCs with elevated levels of FSTL1 secrete CCL3, which interacts with the CCR5 receptor on the surface of HCC cells, thereby activating the PI3K/AKT/mTOR signaling pathway. This pathway activation inhibits anoikis in HCC cells, facilitating their migration, invasion, and growth in vivo. In a nude mouse model, HSCs with high FSTL1 expression significantly enhanced the growth of subcutaneous tumors derived from HCC cells. This was demonstrated by an increased Ki-67 positive index, elevated levels of CCL3 and CCR5 expression, increased Bcl-2 expression, and decreased Caspase-3 expression. In summary, HSCs with high FSTL1 expression inhibit anoikis in HCC cells through the CCL3-CCR5-PI3K/AKT/mTOR axis, thereby promoting tumor progression.

Biochimica et biophysica acta. Molecular basis of disease
Clinical Trial
Landmark Study
PMID: 43003105
2026 Nov 09

Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study.

In a clinical trial, these findings support the potential utility of efinopegdutide as a once-weekly GLP-1-glucagon receptor co-agonist in MASH. Aimed to investigate the efficacy and safety of efinopegdutide in adults with non-cirrhotic MASH.

Lawitz E, Wong VW, Shankar RR, Francque S, Patel K, Miele L, Abdelmalek MF, Krishnan R, Zhang Z, Lam RLH, Golm G, Marquard J, Da BL, Engel SS, Schattenberg JM

Efinopegdutide is a pharmacologically distinct once-weekly GLP-1-glucagon receptor co-agonist with a relative receptor potency balance of approximately 2:1 under development for metabolic dysfunction-associated steatohepatitis (MASH). We aimed to investigate the efficacy and safety of efinopegdutide in adults with non-cirrhotic MASH. We did a phase 2b, randomised, placebo-controlled, double-blind study conducted at 176 academic and community centres in 26 countries. We included adults (aged ≥18 years) with biopsy-confirmed MASH and stage 2 or stage 3 fibrosis. Eligible participants were randomly assigned (1:1:1:1:1) to receive either efinopegdutide (4 mg, 7 mg, or 10 mg), placebo, or open-label semaglutide 2·4 mg, all administered subcutaneously once weekly. Randomisation was performed centrally. The primary endpoint was MASH resolution without worsening of fibrosis at week 52. The key secondary histological endpoint was fibrosis improvement of at least one stage without worsening of steatohepatitis. Missing end-of-treatment biopsies were considered as failure for the primary analysis. This study is registered with EU CT, 2022-502647-35-00, and ClinicalTrials.gov, NCT05877547, and is complete. Between June 23, 2023, and Dec 29, 2025, we screened 1704 participants. We randomly assigned 386 (23%) participants, of whom 381 (99%; 194 [51%] women and 187 [49%] men) received at least one dose of study intervention and were included in the analysis. Baseline characteristics were similar across groups; 239 (63%) of 381 participants had F2 fibrosis and 142 (37%) had F3 fibrosis; the mean age of participants was 53 years (SD 13). At week 52, MASH resolution without worsening of fibrosis occurred in 31 (56%) of 55 participants in the 4 mg efinopegdutide group, 31 (63%) of 49 participants in the 7 mg efinopegdutide group, and 35 (61%) of 57 participants in the 10 mg efinopegdutide group versus seven (13%) of 53 participants in the placebo group (difference vs placebo 43·0 percentage points [95% CI 25·7 to 57·8; p<0·0001] for 4 mg, 49·5 percentage points [31·4 to 64·2; p<0·0001] for 7 mg, and 47·8 percentage points [30·7 to 62·0; p<0·0001] for 10 mg); 26 (53%) of 49 participants receiving semaglutide met this endpoint. For the key secondary endpoint, fibrosis improvement of at least one stage without worsening of steatohepatitis occurred in 32 (43%) of 75 participants in the efinopegdutide 4 mg group, 39 (52%) of 75 participants in the 7 mg efinopegdutide group, and 26 (34%) of 77 participants in the efinopegdutide 10 mg group versus 16 (21%) of 77 participants receiving placebo (difference vs placebo 21·7 percentage points [7·1 to 35·7; p=0·0038] in the efinopegdutide 4 mg group, 30·4 percentage points [15·4 to 44·3; p<0·0001] in the efinopegdutide 7 mg group, and 13·0 percentage points [-1·2 to 26·8; p=0·072] in the efinopegdutide 10 mg group); 16 (25%) of 65 participants receiving semaglutide met this endpoint. The most frequently reported adverse events with efinopegdutide were gastrointestinal, with the highest rates among participants receiving efinopegdutide 10 mg. Adverse events leading to discontinuation of study intervention occurred more frequently among participants receiving efinopegdutide 10 mg (nine [11%] of 79 participants) compared with the other doses of efinopegdutide (range 3-4%) or placebo (one [1%]). Treatment with efinopegdutide resulted in a significantly greater proportion of participants with MASH resolution without worsening of fibrosis compared with placebo. The 7 mg dose showed the most favourable benefit-risk profile, improving fibrosis by at least one stage without worsening steatohepatitis in approximately half of participants after 1 year of treatment. These findings support the potential utility of efinopegdutide as a once-weekly GLP-1-glucagon receptor co-agonist in MASH. Merck Sharp & Dohme, a subsidiary of Merck & Co.

Lancet (London, England)
Other
PMID: 43004510
2026 Nov 09

The Effectiveness of Semaglutide Treatment in Youths with Autism Spectrum Disorder and Obesity: A Real-World Experience.

This study found semaglutide was associated with clinically meaningful weight reduction in youth with ASD and obesity.

Ellis-Miller S, Mahabee-Gittens EM, Kharofa R, Stackpole K, Donohue J, Alzubi A, Siegel R

Youth with autism spectrum disorder (ASD) are at increased risk for obesity, yet data on anti-obesity medications in this population are limited. To evaluate anthropometric and cardiometabolic outcomes associated with semaglutide treatment in youth with ASD and obesity. We performed a retrospective cohort subanalysis of youth aged ≥12 years with ASD and obesity receiving multidisciplinary obesity care. Semaglutide exposure was defined as documentation of weekly dosing of at least 0.5 mg. Outcomes included changes in percentage of the 95th percentile for BMI (%BMIp95), weight, BMI z-score, percent body fat, and cardiometabolic laboratory values. Multivariable linear regression adjusted for baseline outcome value, age, sex, race, insurance, stimulant use, atypical antipsychotic use, other anti-obesity medications, and follow-up duration. Among 120 youth, 20 (16.7%) received semaglutide, and 100 did not. Semaglutide was associated with greater reductions in %BMIp95 (B = -8.11, p = 0.006) and body weight (B = -7.61 kg, p = 0.003). Semaglutide was also associated with a trend toward lower ALT (p = 0.053). Semaglutide was associated with clinically meaningful weight reduction in youth with ASD and obesity.

Childhood obesity (Print)
Review
Notable
PMID: 43003229
2026 Nov 09

Effect of Semaglutide on Dumping Syndrome and Post-Bariatric Hypoglycemia After Roux-en-Y Gastric Bypass: A Single-Center Retrospective Study.

In a research review, variable response and worsening hypoglycemia in a minority support individualized titration and close monitoring.

Eisa N, Khoury M

To evaluate 12-month efficacy and safety of once-weekly semaglutide for refractory post-bariatric hypoglycemia (PBH)/dumping syndrome after Roux-en-Y gastric bypass (RYGB). This single-center retrospective chart review included 100 adults at least 12 months post-RYGB completing 12 months of semaglutide (0.25-2.4 mg/week). Eligibility required Whipple-triad-compatible postprandial symptoms with ambulatory and/or mixed-meal tolerance test support, excluding fasting/non-bariatric hypoglycemia and non-standard anatomy. The primary endpoint was monthly clinically significant hypoglycemic events: Level 3 events requiring assistance and/or verified symptomatic Level 2 events (<54 mg/dL). Participants were 83.0% female, 42.7 ± 7.1 years old, and 2.8 ± 1.4 years post-RYGB; follow-up averaged 14.9 ± 1.8 months. Clinically significant hypoglycemic events decreased from 4.90 ± 2.12 to 3.26 ± 2.68/month at 12 months (p < 0.0001). Complete resolution occurred in 15%, ≥50% reduction without resolution in 26%, suboptimal response in 47%, and worsening hypoglycemia in 12%. Sigstad scores improved from 12.68 ± 2.63 to 9.13 ± 3.82 (p < 0.0001). CGM Time Below Range <54 mg/dL decreased from 5.06% to 2.58%, and Time In Range increased from 61.2% to 76.2% (both p < 0.0001). No serious adverse events occurred; nausea was most common (24.0%). Semaglutide was associated with fewer clinically significant hypoglycemic events, improved dumping symptoms, and better CGM metrics over 12 months. Variable response and worsening hypoglycemia in a minority support individualized titration and close monitoring.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Other
PMID: 43002249
2026 Nov 09

The role of central monoamines in the positive reinforcing effects of affective touch.

In a rat study, these data also suggest that MDMA may not reproduce in rodents the entactogenic effects commonly reported in humans and some nonhuman primate studies.

Baidwan T, Folger KJ, Foley CM, Smith MA

Affective touch can produce positive emotional states and serves as a critical component of social bonding. Although the circuitry of affective touch has been well characterized, the role of central monoamines in the functional consequences of affective touch has not been systematically examined. The objective of this study was to examine the role of monoamines in the positive reinforcing effects of affective touch METHODS: Male and female rats were treated with selective monoamine reuptake inhibitors (GBR 12909, atomoxetine, fluoxetine) and nonselective monoamine releasers/reuptake inhibitors (amphetamine, cocaine, MDMA) and placed into an apparatus divided into two equally sized areas. When rats were in the "touch" area, they were "petted" by a blinded experimenter; when rats were in the "no touch" area, they were left undisturbed. All drugs were tested across a 10-fold dose range, and saline and oxytocin were tested as negative and positive controls, respectively. Affective touch served as a positive reinforcer as indicated by a preference for the "touch" area. Oxytocin, the nonselective monoamine reuptake inhibitor cocaine, and the nonselective monoamine releaser amphetamine robustly increased the reinforcing effects of touch. To a lesser degree, the selective dopamine reuptake inhibitor GBR 12909 increased the reinforcing effects of touch, whereas the nonselective monoamine releaser/reuptake inhibitor MDMA decreased the reinforcing effects of touch. These data suggest that drugs that increase synaptic dopamine, particularly those with high addiction liability, increase the positive reinforcing effects of affective touch. These data also suggest that MDMA may not reproduce in rodents the entactogenic effects commonly reported in humans and some nonhuman primate studies.

Psychopharmacology
Review
Notable
PMID: 42998725
2026 Nov 07

Phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience.

In a research review, gastrointestinal events, particularly nausea, vomiting, diarrhoea and constipation, were the predominant adverse effects, while overall tolerability remained consistent with the established GLP-1RA profile.

Patel SK, Dubey S, Tiwari A

Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), has become an important therapeutic agent for type 2 diabetes mellitus (T2DM), obesity, and associated cardiometabolic complications. Its prolonged pharmacological activity and availability as subcutaneous and oral formulations have supported extensive clinical development across diverse populations. This review critically evaluates Phase 3, Phase 3a, and Phase 3b clinical trials (CTs) assessing the efficacy, safety and therapeutic utility of semaglutide, with an emphasis on the SUSTAIN, PIONEER, STEP, SELECT, FLOW, SOUL and related programmes. Eligible trials were assessed according to study design, registration, treatment duration, population characteristics, interventions, comparators, primary endpoints, adverse events (AEs) and clinical significance. Collectively, the evidence demonstrates clinically meaningful improvements in glycaemic control and body weight, as well as cardiovascular and renal benefits, in selected populations. Evidence from obesity and post-bariatric studies further supports its expanding therapeutic role beyond conventional glucose management. Gastrointestinal events, particularly nausea, vomiting, diarrhoea and constipation, were the predominant adverse effects, while overall tolerability remained consistent with the established GLP-1RA profile. However, differences in populations, treatment duration, comparators and endpoint definitions highlight important evidence gaps. This review synthesises Phase 3 clinical evidence to define the evolving therapeutic position, safety profile and future research priorities for semaglutide.

Diabetes research and clinical practice
Animal Study
Notable
PMID: 42998397
2026 Nov 07

N-terminal 24-amino acid fragment (GI24) of the 36-amino acid peptide PMAP-36 (porcine myeloid antimicrobial peptide 36) exhibits antiviral activity against porcine reproductive and respiratory syndrome virus in vitro.

In an animal study, collectively, our data reveal that porcine-derived antimicrobial peptides inhibited PRRSV infection and suppressing pro-infammatory responses. Screened and identified PMAP-36, a member of linear porcine myeloid antimicrobial peptides (PMAPs) from the porcine cathelicidin family, which exhibits prominent antiviral activity against PRRSV.

Wen B, Liu Z, Zhang H, Mu X, Wang N, Li X, Liu S, Sun H, Wang R, Shen J, Li M, Zhang L, Hu J, Wang L, Ding K

Given vaccine strategies provide limited protection against porcine reproductive and respiratory syndrome virus (PRRSV) prevalence and transmission, there is an urgent demand for developing novel antiviral strategies against to combat this pathogen. Antimicrobial peptides are known to possess antiviral activity against viruses. In this study, We screened and identified PMAP-36, a member of linear porcine myeloid antimicrobial peptides (PMAPs) from the porcine cathelicidin family, which exhibits prominent antiviral activity against PRRSV. Furthermore, the N-terminal 24-amino acid fragment (GI24) of the 36-amino acid peptide PMAP-36 serves as the key active region responsible for its antiviral function, as it robustly inhibits both PRRSV attachment and cellular entry. We also show that GI24 exerts anti-inflammatory effects, as it suppresses the expression of pro-inflammatory cytokines and the activation of inflammatory signaling pathways induced by both PRRSV and Lipopolysaccharide (LPS). Additionally, we demonstrate that TREM1 is a crucial target gene mediating the anti-inflammatory effects of GI24. Collectively, our data reveal that porcine-derived antimicrobial peptides inhibited PRRSV infection and suppressing pro-infammatory responses. Therefore, porcine cathelicidin-derived antimicrobial peptides represent excellent candidates for the development of potential therapeutic agents against PRRSV infection.

Animal Study
Notable
PMID: 42995292
2026 Nov 07

NAD+ as a metabolic immune checkpoint in cancer.

In an animal study, throughout, findings that are experimentally established are separated from those that remain contested or hypothetical, and the criteria under which the checkpoint designation is analytically useful, together with the conditions under which it is not, are stated explicitly.

Izadpanah R, Alt EU

Nicotinamide adenine dinucleotide (NAD+) functions in cancer as a compartmentalized signaling currency, coupling tumor cell fitness to immune competence within the tumor microenvironment (TME). In malignant cells, NAD+ sustains redox balance, poly(ADP-ribose) polymerase (PARP)-dependent DNA repair, sirtuin-mediated chromatin remodeling, and metabolic stress adaptation. In immune effector cells, the same metabolite governs mitochondrial integrity, effector persistence, and resistance to exhaustion. This duality is the basis of the explanation advanced here for why first-generation inhibitors of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting salvage pathway enzyme, failed clinically when deployed as cytotoxic monotherapies without an immunometabolic rationale. This review synthesizes the field around a central premise: NAD+ operates as a context-dependent metabolic immune checkpoint whose therapeutic value depends on where in the tumor immune ecosystem the pathway is perturbed and whether checkpoint blockade is deployed concurrently. The therapeutic landscape is reorganized around five pharmacological classes, which differ in how far each has been tested: (i) NAMPT catalytic inhibitors, evaluated clinically and withdrawn; (ii) bifunctional NAMPT/programmed death-ligand (PD-L1) compounds and proteolysis-targeting chimera (PROTAC)-mediated NAMPT degradation, both preclinical; (iii) NAD+ precursor-based immunorestorative strategies, including ex vivo rescue of age-associated chimeric antigen receptor T (CAR-T) cell dysfunction through NMN/CD38 inhibitor combinations; (iv) adenosinergic axis targeting, in which anti-CD38 and anti-CD73 agents are approved or in trials while the proposed triple-blockade of CD38, CD73, and PD-1/PD-L1 remains untested; and (v) combinations with PARP and indoleamine 2,3-dioxygenase (IDO) inhibitors, which rest on mechanistic rationale. A tripartite pharmacological taxonomy distinguishes intracellular (iNAMPT), extracellular (eNAMPT), and vesicle-associated (vNAMPT) NAMPT as discrete drug targets. The analyses examines how TME acidification, precursor competition, and extracellular NAD+ catabolism through the CD38-CD203a-CD73 noncanonical adenosine axis reshape immune fitness, and why biomarker-guided separation of tumor-directed NAD+ depletion from immune-directed NAD+ restoration is required for rational clinical translation. Throughout, findings that are experimentally established are separated from those that remain contested or hypothetical, and the criteria under which the checkpoint designation is analytically useful, together with the conditions under which it is not, are stated explicitly.

Cancer metastasis reviews
Animal Study
Notable
PMID: 42998857
2026 Nov 07

Mangiferin Buffers Depressive-Like Behaviors by Modulating Astrocytic DHHC2 in the Hippocampus.

In a mouse study, mangiferin, a compound from tropical plants, reduced anxiety and depression-like behaviors induced by chronic stress. The protective effect occurred through activation of antioxidant signaling specifically in brain astrocytes, a type of support cell, rather than neurons.

Xia ZX, Zhao YL, Tian D, Zhang XT, Wang SY, Cao HY, Ding QQ, Zheng L, Zheng HP, Du GK, Zhang Y, Cao T, Tao WC, Chen Z, Luo YX, Shen ZC

Several lines of evidence indicate that mangiferin (MGF) ameliorates chronic stress-induced anxiety- and depressive-like behaviors, yet its precise role and underlying mechanisms remain poorly understood. Here, we show that MGF effectively alleviates anxiety- and depressive-like behaviors in mice exposed to chronic stress, accompanied by reduced synaptic loss and ameliorated hippocampal neurogenesis deficits. Notably, nuclear factor erythroid 2-related factor 2 (Nrf2) expression is preferentially altered in hippocampal astrocytes but not in neurons or microglia after chronic stress and MGF treatment, and knockdown of astrocytic Nrf2 abrogates the antidepressant effect of MGF. Further mechanistic studies showed that MGF reverses reactive astrogliosis by regulating astrocytic DHHC2-Nrf2 signaling, including Nrf2 palmitoylation and its nuclear translocation, thereby protecting Nrf2 from Keap1-mediated ubiquitination and proteasomal degradation and sustaining its transcriptional activity in reactive astrocytes. These findings demonstrate that MGF alleviates chronic stress-induced anxiety- and depressive-like behaviors by engaging the astrocytic DHHC2-Nrf2 signaling, suppressing reactive astrogliosis and reversing hippocampal synaptic and neurogenic deficits, which provides novel insights into the therapeutic potential of MGF for chronic stress-related mood disorders.

Pharmacological research
Review
Notable
DOI
2026-11-06

Real-World Use, Dosing, and Reported Side Effects of BPC-157 and TB-500 for Musculoskeletal Injury: An Analysis of Online Communities

In a rat study, these findings may inform regulatory decisions on pharmacy compounding. Objective To describe how people use the unapproved peptides BPC-157 and TB-500 for tendon, ligament and muscle injury and what side effects they report.

Cassinat J, Callan C, Liggett C, Wright V.

Objective To describe how people use the unapproved peptides BPC-157 and TB-500 for tendon, ligament and muscle injury and what side effects they report. Methods Using a large language model validated against physician review, we analyzed 92,254 posts and comments from 28,652 users in Reddit’s peptide communities from 2021 to 2026. We compared side effects with those reported by users of four other peptides in the same communities. Results In all, 5,588 users described using BPC-157 and/or TB-500 for a specific musculoskeletal injury, most often a chronic tendon problem of the shoulder, knee or elbow. Only 3.8% of users described physician involvement, and 90.9% of those naming a source bought from research-chemical vendors. The median BPC-157 dose (366 µg per injection) was about 2.7 times the human-equivalent dose of the 10 µg/kg rat regimen, and among new users it rose from 300 µg in 2024 to 500 µg in 2025. Of those stating an outcome, 79.3% reported improvement, and 36.6% of all users were also in physical therapy. Overall, 27.2% described at least one side effect, most often fatigue, anxiety, anhedonia and insomnia. Anhedonia was more common than among users of the four other peptides (10.2% versus 1.3% of those with side effects). Conclusion Use of these unapproved peptides for musculoskeletal injury is largely unsupervised, relying on grey-market products at self-selected, rising doses without established safety or efficacy. What is already known on this topic Evidence that BPC-157 and TB-500 help tendon, ligament or muscle injury comes almost entirely from animal studies. Both are prohibited in sport by the World Anti-Doping Agency, and in July 2026 a US Food and Drug Administration advisory committee voted to recommend them for pharmacy compounding. What this study adds We analyzed over 90,000 Reddit posts from 5,588 users taking these peptides for a specific injury, most often a chronic tendon problem of the shoulder, knee or elbow. Only 3.8% described physician involvement, and 90.9% of those naming a source bought from research-chemical vendors. The median BPC-157 dose was about 2.7 times the human-equivalent dose of the rat regimen, and 27.2% of users reported a side effect. Anhedonia was about eight times as common as among users of four other peptides in the same communities. How this study might affect research, practice or policy Clinicians treating chronic tendon problems should ask about peptide use and counsel patients on the lack of human efficacy data, unregulated supply, anti-doping status and reported side effects. Trials with prespecified neuropsychiatric outcomes are needed before any benefit or dose can be claimed. These findings may inform regulatory decisions on pharmacy compounding.